Haematologic malignancies
Ascentage Pharma Group Inc. focuses on blood cancers including acute myeloid leukemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, chronic myeloid leukemia, and Philadelphia chromosome-positive acute lymphoblastic leukemia. Its clinical work also extends to myelodysplastic syndrome, with attention to both newly diagnosed and relapsed or refractory disease settings.
- Acute myeloid leukemia
- Chronic lymphocytic leukemia and small lymphocytic lymphoma
- Chronic myeloid leukemia
- Philadelphia chromosome-positive acute lymphoblastic leukemia
- Myelodysplastic syndrome
The sponsor’s portfolio includes therapies for both frontline and previously treated haematologic cancers, with a strong concentration on lymphoid malignancies and myeloid neoplasms.
B-cell malignancies and CLL/SLL
A major area of interest is chronic lymphocytic leukemia and small lymphocytic lymphoma, including newly diagnosed, treatment-naïve, and relapsed and/or refractory disease. The research landscape includes combinations with BTK inhibitors, anti-CD20 therapy, and other targeted approaches used in B-cell malignancies.
- Previously treated CLL/SLL
- Treatment-naïve CLL/SLL
- Relapsed and/or refractory CLL/SLL
- BTK inhibitor-based combinations
- Anti-CD20-based regimens
Clinical activity in this area reflects sustained interest in targeted treatment strategies for lymphoproliferative disorders and disease control across multiple lines of therapy.
Targeted therapy in acute leukemia
The sponsor is active in acute leukemia research, especially newly diagnosed acute myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Its studies explore targeted agents alongside established chemotherapy or epigenetic therapy for patients who are older or unable to receive intensive induction treatment.
- Newly diagnosed AML
- Newly diagnosed Ph+ ALL
- Chemotherapy-based combinations
- Tyrosine kinase inhibitor strategies
- Older or unfit patients
This area highlights interest in molecularly defined leukaemias and treatment approaches aimed at improving disease response in high-risk haematologic cancers.
Chronic myeloid leukemia and molecular response
Another focus is chronic phase chronic myeloid leukemia, including patients with T315I mutation and other treatment-resistant disease features. The clinical programme centres on tyrosine kinase inhibitor therapy and the pursuit of deep molecular responses in CML-CP.
- Chronic phase CML
- T315I-mutated CML
- Tyrosine kinase inhibitor therapy
- Molecular response assessment
The sponsor’s work in this domain is directed toward resistant chronic myeloid leukemia and precision treatment options for genetically defined subgroups.
